Please assess the completion status of the following clinical trial:

Trial Title: Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 year old undergoing transcatheter ASD closure with the Amplatzer Septal Occluder device (AGA medical Corp., MN, USA).~* Female subjects must be post-menopausal, surgically sterile, or using an effective method of birth control.~* Signed an informed consent document.~Exclusion Criteria:~* Allergy or intolerance to any of the antithrombotic drugs (aspirin, clopidogrel) used in the study.~* Need for anticoagulation therapy.~* Use of ASD closure devices other than the Amplatzer Septal Occluder device.~* History of migraine headaches (based on migraine headache questionnaire).~* Refusal to sign the informed consent.~* Pregnancy or breast-feeding or planning to become pregnant during the study.~* Previous stroke.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin + clopidogrel (Type: EXPERIMENTAL): Aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
- Aspirin (Type: ACTIVE_COMPARATOR): Aspirin (80 mg/day) for 3 months following ASD closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).